Leukemia & lymphoma/Leukemia and lymphoma · 2014 · 34 citations · 22 references
MedicineNuclear MedicineOncologyDiagnostic ImagingDiagnostic RadiologyOncologic ImagingComputed TomographyHematologic MalignanciesLymphoid TumorsLymphoma ImagingPositron Emission TomographyBone Marrow Involvement AssessmentEnlarged Lymph NodesHodgkin Lymphoma ImagingHodgkin Lymphoma TreatmentLymphoma StagingPet-computed TomographyPositron Emission Tomography FindingsTreatment Modality Selection
We compared initial computed tomography (CT) and positron emission tomography (PET)/CT in 96 patients with Hodgkin lymphoma (HL), assessing the role of baseline PET/CT in stage migration and treatment selection. The number of patients with stage I, II, III and IV disease based on CT versus PET/CT was: 5 vs. 7, 49 vs. 37, 28 vs. 22 and 14 vs. 30, respectively. In 33 (34%) patients, PET/CT changed HL stage: 27 (28%) were upstaged and six (6.3%) downstaged. Upstaging was caused by detection of new extranodal involvements (47 sites in 26 patients): bone marrow (10 patients), spleen (five patients) and lung (two patients). In nine patients≥2 further coexisting locations were detected. Downstaging resulted from the absence of fluorodeoxyglucose (18F-FDG) uptake in enlarged nodes (>15 mm) in the abdomen and pelvis. PET/CT modified HL stage in 34% of patients leading to treatment modification in the majority. Our results indicate that PET/CT should be mandatory in the initial staging of HL.
22
<sup>18</sup>F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
Michal Weiler‐Sagie, Olga Bushelev, Ron Epelbaum et al. · Journal of Nuclear Medicine · 2009 · 381 citations
Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography
Robert Carr, Sally F. Barrington, Bella Madan et al. · Blood · 1998 · 308 citations · Full text
Tarec Christoffer El‐Galaly, Francesco d’Amore, Karen Juul Mylam et al. · Journal of Clinical Oncology · 2012 · 290 citations · Full text
Medicine, Nuclear Medicine, Oncology +17